You are here: Industry Insights > metabolic

News List

osteolabs Successfully Demonstrates Broader Application of its Technology for Chronic Kidney Disease and Bone Metastasis-related Prostate Cancer PharmaSources
January 19, 2023
So far osteolabs has successfully applied its proprietary Calcium Isotope Marker Technology for the early detection and therapy monitoring in the field of osteoporosis.
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations PharmaSources.com
January 05, 2023
HighTide Therapeutics announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital. Other investors included Yuexiu Fund and Yuthai Fund.
Takeda sells select non-core assets in Europe to Cheplapharm for about $562 mn expresspharma
September 17, 2020
Portfolio includes prescription products in Takeda’s cardiovascular/metabolic and anti-inflammatory therapeutic areas along with calcium.
Metabolic Surgery May Reduce CV Risk in T2DM With Obesity drugs
September 05, 2019
For patients with type 2 diabetes and obesity, metabolic surgery is associated with a reduced risk for mortality and major adverse cardiovascular events...
BP, Waist Circumference, Lipids Should Be Measured Regularly drugs
August 06, 2019
Blood pressure, waist circumference, fasting lipid profile, and blood glucose should be measured regularly to identify atherosclerotic cardiovascular disease (ASCVD)...
Merck and Utah University find potential diabetes drug target pharmaceutical-technology
July 09, 2019
Merck Research Laboratories and the University of Utah Health have shown that deactivation of the dihydroceramide desaturase 1 (DES1) enzyme could offer a potential drug target for metabolic diabetes.
Review Suggests More Sleep May Lower Cardiometabolic Risk drugs
June 18, 2019
Review Suggests More Sleep May Lower Cardiometabolic Risk.
Irregular Sleep Patterns May Increase Risk for Metabolic Syndrome drugs
June 11, 2019
Irregular Sleep Patterns May Increase Risk for Metabolic Syndrome.
Lipocine Announces Tlando NDA PDUFA Action Date of November 9, 2019 drugs
May 15, 2019
Lipocine Announces Tlando NDA PDUFA Action Date of November 9, 2019.
Deuterium Depletion is a Disruptive Innovation in the Pharma Industry - HYD Pharma Develops New Deuterium-Depleted Drugs for the Treatment of Neoplastic and Metabolic Diseases b3cnewswire
April 17, 2019
Deuterium Depletion is a Disruptive Innovation in the Pharma Industry...

Previous page 1 2 Next page